PubMed Trending Research Digest — September 04, 2026

Automated digest · 97 articles · 15 research areas · September 04, 2026

Overview

Across this week’s set of papers, a dominant theme is prevention and risk reduction—especially for respiratory viruses and cardiometabolic disease. Multiple systematic reviews update vaccine effectiveness and safety for influenza and RSV (and COVID-19 for the 2026–2027 season), reinforcing that vaccination meaningfully reduces severe outcomes in high-risk groups. In parallel, obesity and metabolic liver disease (MASLD/MASH) research spans clinical pharmacotherapy landscapes, geroprotective effects of GLP-1 signaling (semaglutide in mice), and postmarketing safety surveillance of incretin-based drugs—together highlighting how metabolic interventions are moving from symptom control toward broader disease-modifying and system-level risk management.

A second major thread is immunology as both a therapeutic target and a mechanistic lens on disease. Cancer studies repeatedly connect treatment response to microenvironment architecture (e.g., B-cell lymphoid aggregates in melanoma brain metastases), immune evasion via transcriptional control (cyclin E–CDK2→BRD4 interferon program repression), and immune suppression through nutrient/ROS deprivation (tumor antioxidants via PRDX1). Complementary work in infectious disease and host defense (influenza PA-X host shutoff, MPXV replisome structure, TB epimerase complex structures, and bacterial reverse transcriptase defense activation) underscores a broader emphasis on molecular mechanisms that can be exploited for antiviral or immunomodulatory strategies.

Finally, several studies advance translational infrastructure—guidelines, biomarkers, and delivery platforms. Delphi and guideline efforts standardize care across diverse settings (severe alopecia areata, ocular toxoplasmosis imaging workflows, biliary stricture endoscopy, and psychological prehabilitation), while biomarker-driven approaches appear in multiple forms: exosomal miRNA models for occult liver metastasis, MRD and genetics for hematologic risk stratification, and multi-omics/proteomic signatures for sex-specific CAD risk. On the technology side, programmable delivery systems (exosomes, LNP/RNA vehicles, mitochondria-transfer nanovesicles) and engineered immune-cell therapies (dual-target CAR T, MAIT receptor/checkpoint tuning) reflect a field converging on more precise, mechanism-informed interventions.

---

Surgery, Perioperative Care & Clinical Guidelines (including anesthesia/consensus)

Biliary stricture management: European Society of Gastrointestinal Endoscopy (ESGE) Guideline.

This ESGE guideline evaluated evidence for endoscopic management of benign biliary strictures in patients requiring treatment after postcholecystectomy or liver-transplantation complications. It recommends temporary placement of multiple plastic stents (MPSs) for postcholecystectomy benign biliary strictures, with consideration of a fully covered self-expandable metal stent (FCSEMS) when the stricture is >2 cm from the main hepatic confluence or when patients are noncompliant with repeated ERCPs, and it recommends MPSs or temporary FCSEMS for anastomotic strictures after liver transplantation when similarly located >2 cm distally. Clinically, these recommendations standardize stent selection and timing to improve outcomes and reduce procedural burden in biliary stricture care.

Lemmers A, Tringali A, Teles de Campos S et al. · Endoscopy · (2026) · View on PubMed ↗

Parental depression in offspring’s internalization of stigma: A family-individual model of self-stigma.

This study investigated how parental depression influences offspring self-stigma through a family–individual model in Chinese individuals with depression aged 13–30 years. Using a survey of 1,012 participants and statistical modeling (t tests/chi-square tests and structural equation modeling), it found that parental depression is associated with greater offspring internalization of stigma via pathways involving both familial and individual factors. Clinically, the results highlight parental depression as a modifiable contextual risk factor for self-stigma and help inform targeted family-informed interventions.

Du N, Huang YT · The American journal of orthopsychiatry · (2026) · View on PubMed ↗

Prioritising Psychological Prehabilitation Interventions for Cancer Surgery: An International Delphi Study.

This international Delphi study sought expert consensus on preferred psychological prehabilitation interventions for patients undergoing urogenital, thoracic, or gastrointestinal cancer surgery. Across a three-round Delphi process (Feb–Sep 2025), the panel aimed to standardize which psychological components are perceived as most effective and to map current real-world delivery practices. Establishing consensus could reduce fragmentation of preoperative mental health support and potentially improve postoperative recovery outcomes in surgical oncology.

Hirst N, Gates J, Dhillon HM et al. · ANZ journal of surgery · (2026) · View on PubMed ↗

Prophylactic intravenous dexamethasone is associated with reduced cutaneous toxicity during first-line enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma: a multicenter prospective cohort study.

This multicenter prospective cohort study tested whether prophylactic intravenous dexamethasone reduces cutaneous toxicity in patients receiving first-line enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma. Among 172 Japanese patients across 11 institutions, three institutions used fixed dexamethasone premedication (6.6 mg) while eight did not, and the primary endpoint was any-grade skin reaction. If prophylaxis lowers skin toxicity, it could support practical supportive-care strategies to improve tolerability of enfortumab vedotin–pembrolizumab.

Taoka R, Tamura K, Tsujino T et al. · International journal of clinical oncology · (2026) · View on PubMed ↗

Well-being differences and changes in people with somatic and psychiatric disorders or multimorbidities: modelling COVID-19 as a global natural experiment of stress vulnerability.

The study modeled COVID-19 as a global natural experiment to identify disorder profiles associated with lower well-being and greater well-being decline under stress using the Collaborative Outcomes Study on Health and Functioning during Infection Times survey. It analyzed WHO-5 well-being scores retrospectively pre-pandemic and intra-pandemic with mixed-effects models controlling for demographic and pandemic-related covariates to estimate baseline well-being and stress-related change across somatic and psychiatric disorders and multimorbidities. This helps characterize stress-vulnerability patterns that could guide targeted support for people at highest risk of well-being deterioration during widespread stressors.

Adam TJ, Thompson T, Peroz FH et al. · BMJ mental health · (2026) · View on PubMed ↗ · Free PDF ↗

Spinal versus general anaesthesia and serious complications in older patients undergoing hip fracture surgery in Germany: a multicentre randomised clinical trial.

This multicentre pragmatic randomized clinical trial (iHOPE) studied spinal versus general anaesthesia in older adults (≥65 years) undergoing hip fracture surgery across 22 German hospitals. The key finding was the comparative effect of anaesthetic technique on all-cause mortality and new-onset serious cardiac and pulmonary complications, with patients randomized to general anaesthesia (n=389) or spinal anaesthesia (n=386). The results are clinically significant because they inform anaesthetic choice in a high-risk geriatric surgical population where evidence has been limited.

Kowark A, Schoenen S, Schmidt R et al. · The lancet. Healthy longevity · (2027) · 1 citations · View on PubMed ↗ · Free PDF ↗

Gestational Changes in Antiseizure Medication Concentrations and the Impact of Polytherapy: A Prospective Multicenter Cohort Study in China.

This prospective multicenter observational cohort study in China measured gestational changes in antiseizure medication (ASM) pharmacokinetics in women with epilepsy aged 18–45 years. Using steady-state trough concentrations and concentration-to-dose (C/D) ratios analyzed with linear mixed-effects models, it quantified how gestational age and polytherapy affect ASM levels. Clinically, the findings support more individualized ASM monitoring and dosing during pregnancy to reduce seizure risk and toxicity.

Duan Y, Huang S, Sha L et al. · Neurology · (2026) · View on PubMed ↗

Serial Ketamine Infusions for Treatment-Resistant Bipolar Depression: A Randomized Clinical Trial.

This randomized clinical trial studied adjunctive intravenous ketamine versus midazolam for treatment-resistant bipolar I or II depression in adults with treatment-resistant bipolar depression (Ket-BD study) across three sites in Ontario, Canada. The trial evaluated efficacy, safety, and tolerability of serial ketamine infusions in this specific bipolar population. If effective and safe, ketamine could provide a targeted, evidence-based option for TRBD where current antidepressant strategies are limited by mood-switch risk.

Orsini DK, Di Luch S, Tomlinson G et al. · JAMA psychiatry · (2026) · View on PubMed ↗

Delphi Consensus Statement on Treatment of Severe Alopecia Areata in US Adults.

This Delphi consensus statement studied evidence and expert agreement to standardize treatment recommendations for severe alopecia areata in US adults, synthesizing randomized clinical trial data across therapies. The consensus was developed from systematic literature reviews (through December 2024) and structured expert rounds to reach predefined agreement levels. Establishing uniform guidance before widespread Janus kinase inhibitor adoption aims to improve treatment outcomes and payer coverage for severe AA.

Gregoire S, Dewey E, Biba U et al. · JAMA dermatology · (2026) · View on PubMed ↗

Superlarge-Bore Versus Large-Bore Aspiration Catheters in Mechanical Thrombectomy: A Multicenter Propensity-Matched Analysis.

This multicenter retrospective propensity-matched analysis compared superlarge-bore (SLB) versus large-bore (LB) aspiration catheters as the first-attempt device in acute ischemic stroke (AIS) patients with large vessel occlusion treated at 34 international centers from 2018–2025. Using propensity score matching (1:6) to balance baseline and technical confounders, it evaluated procedural safety and efficacy outcomes between catheter sizes. The findings help determine whether SLB aspiration catheters improve first-pass performance and safety compared with LB catheters in real-world thrombectomy practice.

Chacon A, Alawieh AM, Motiwala M et al. · Neurosurgery · (2026) · View on PubMed ↗

---

Bioengineering & Drug Delivery Platforms (exosomes/LNP/RNA vehicles/nanovesicles)

Porcine kidney xenotransplantation as a bridge to allotransplantation: a first-in-human study.

This first-in-human study investigated whether a gene-edited porcine kidney xenograft (EGEN-2784) could serve as a bridge to subsequent human allotransplantation in a living recipient with end-stage kidney disease and prolonged expected wait time for deceased donor transplantation. The key finding was successful sequential transplantation strategy using the xenograft followed by allotransplantation, addressing concerns about durability and immunologic sensitization that could complicate later allografting. Scientifically and clinically, it supports the feasibility of using gene-edited pig kidneys to mitigate organ shortages while preserving the option for definitive allotransplantation.

Riella LV, Borges TJ, Rosales IA et al. · Lancet (London, England) · (2026) · 1 citations · View on PubMed ↗

Creating bottom-up RNA transfer vehicles from synthetic protein assemblies.

The study explored whether AI-designed synthetic protein assemblies can be engineered into bottom-up RNA transfer vehicles independent of viral evolution. It found that functional nucleic acid transport vehicles can be created by assembling designed protein architectures to package and deliver RNA. This advances non-viral RNA delivery platforms by providing a programmable route to build transfer systems with controllable structure and function.

Schuhmacher MK, Gruber C, Lang CMR et al. · Nature · (2026) · View on PubMed ↗ · Free PDF ↗

Rewiring the ribosome to translate proteins encoded in its own RNA.

The study tested whether bacterial ribosomes can be engineered to translate proteins encoded in their own RNA by integrating protein-coding information into the ribosome itself, focusing on translation of ribosomal RNA (rRNA). It found that ribosomes can be rewired to translate proteins encoded in their own rRNA, demonstrating feasibility of self-encoded translation. This supports both biotechnology concepts for dedicated translation systems and RNA-world hypotheses about early, reliable protein synthesis.

Alizadeh K, Klepacki D, Vázquez-Laslop N et al. · Nature · (2026) · View on PubMed ↗

Airway administered artificial mitochondria-enriched nanovesicles for efficient and selective mitochondria transfer to intervene in pulmonary fibrosis.

The study developed mesenchymal stem cell-derived biomimetic nanovesicles enriched with mitochondria and tested airway administration for selective mitochondrial transfer to injured cells in the context of pulmonary fibrosis. It found that the nanovesicles had high mitochondrial loading capacity, increased extracellular mitochondrial stability, and efficiently delivered mitochondrial cargo selectively to injured cells. This supports a potentially translatable, noninvasive mitochondria-transfer strategy for restoring mitochondrial homeostasis in pulmonary fibrosis.

Zhang J, Fu S, Wang J et al. · Nature communications · (2026) · View on PubMed ↗ · Free PDF ↗

An Exosomal Signature for Preoperative Detection of Occult Liver Metastasis in Pancreatic Cancer.

The study developed and externally validated a circulating exosomal microRNA (exo-miRNA) machine-learning model for preoperative detection of occult early liver metastasis in patients with pancreatic ductal adenocarcinoma undergoing pancreatectomy. Using exo-miRNA sequencing in a genome-wide discovery cohort and then training and independent external validation cohorts, the model identified patients with occult liver micrometastasis preoperatively. This could improve surgical decision-making and risk stratification by detecting an aggressive PDAC phenotype before metastases become clinically apparent.

Noma T, Yin J, Zhang J et al. · JAMA surgery · (2026) · View on PubMed ↗

---

Neurology & Neuroinflammation (MS/ALS/brain aging/microglia)

Aging microenvironment induces CD8+ T cell exhaustion by suppressing hepatic β-hydroxybutyrylate synthesis.

This study examined how aging alters hepatic metabolism to drive CD8+ T cell exhaustion in the context of antiviral and antitumor immunity. It found that the aged microenvironment reduces β-hydroxybutyrate (3HB) bioavailability by repressing BDH1-dependent hepatic 3HB synthesis and limiting SLC16A1-mediated 3HB uptake, and that hepatic BDH1 ablation reproduces age-associated CD8+ dysfunction while 3HB supplementation reverses it via β-hydroxybutyrylation signaling with PRKAR1B identified as a primary effector using a 3HB-derived chemical probe (3Halk) and functional screening. These results suggest targeting the BDH1–3HB–PRKAR1B axis to restore CD8+ T cell function during aging.

Xiao Y, Zhang Y, Zhao Z et al. · Cell metabolism · (2026) · View on PubMed ↗

Sexual dimorphism in the complete Drosophila male central nervous system connectome.

This work studied sex differences in the Drosophila male brain by generating and analyzing the complete male central nervous system connectome and comparing it with the female connectome at synaptic resolution. The key finding was that, among 11,710 neuron types, there are 8,069 isomorphic, 138 dimorphic, 289 male-specific, and 71 female-specific types, with the connectome annotated for fruitless/doublesex expression to link transcriptional dimorphism to circuit organization. Scientifically, it provides a comprehensive wiring-level resource to explain how sex-specific gene programs shape functional neural circuits and behavior.

Berg S, Beckett IR, Costa M et al. · Cell · (2026) · View on PubMed ↗ · Free PDF ↗

Intracellular complement factor H protects neurons during CNS inflammation.

The study examined neuron-intrinsic mechanisms of resilience in multiple sclerosis (MS) by analyzing retinal ganglion cells (RGCs) from MS donors and controls using single-nucleus RNA sequencing. It found that intracellular complement factor H (CFH) expression in neurons strongly correlated with resilience-associated transcriptional programs. This identifies CFH as a potential protective target for limiting neurodegeneration during CNS inflammation.

Mayer C, Woo MS, Sonner JK et al. · Nature · (2026) · View on PubMed ↗ · Free PDF ↗

Somatic mutations reveal the ontogeny of microglia in human ageing.

The study used accumulated somatic mutations as clonal barcodes to track bone-marrow-derived cell infiltration into the human brain and infer microglial ontogeny during ageing in 20 older individuals. It found evidence that somatic-mutation labeling reveals the timing and extent of microglial clonal contributions consistent with bone-marrow-derived origins in human ageing. This clarifies how human microglia are maintained and replenished over the lifespan, informing models of neuroinflammation and age-related brain disease.

Belk JA, Zhang Y, Reilly EE et al. · Nature · (2026) · View on PubMed ↗

Mitochondrial calcium influx-driven bioenergetics selectively enable drug addiction.

The study examined how opioids and methamphetamine affect mitochondrial calcium (Ca2+) influx in dopaminergic terminals of the nucleus accumbens, focusing on the mitochondrial calcium uniporter (MCU) and using optogenetic stimulation to control dopamine neuron firing intensity. It found that opioids and methamphetamine—but not natural rewards—trigger MCU-dependent mitochondrial Ca2+ influx selectively during high-intensity dopaminergic activation, and that this bioenergetic mechanism selectively enables addiction-related dopamine release and behaviors. This identifies an MCU/mitochondrial Ca2+–linked circuit mechanism that could be therapeutically targeted to suppress drug addiction without broadly disrupting natural reward processing.

Gao J, Zhao H, Han X et al. · Nature neuroscience · (2026) · View on PubMed ↗

Repairing the Amyotrophic Lateral Sclerosis Trial Credibility Gap.

This article discusses the scientific and methodological reasons why early- and mid-phase amyotrophic lateral sclerosis (ALS) trial findings often fail to translate into successful phase 3 outcomes. It highlights recurring fallacies such as incorrect outcome comparisons, misuse of biomarkers, selective reporting, and overreliance on post hoc analyses driven by incentives in the “clinical trial industrial complex.” The significance is that it provides a framework for improving trial design, analysis, and reporting to increase the credibility of ALS clinical evidence.

Benatar M, Rothstein JD, Snow K et al. · Neurology · (2026) · View on PubMed ↗ · Free PDF ↗

---

Cancer Immunotherapy & Tumor Microenvironment (Mechanisms/Biomarkers)

Psilocybin prevents chemotherapy-induced peripheral neuropathy through mitochondrial trafficking preservation.

This study tested whether psilocybin can prevent chemotherapy-induced peripheral neuropathy (CIPN) in preclinical platinum- and taxane-based models, including repeated chemotherapy cycles. It found that as few as two psilocybin doses given before chemotherapy durably prevented CIPN onset without impairing antitumor efficacy, preserving tactile sensitivity and intraepidermal nerve fiber endings by maintaining axonal mitochondrial trafficking and distribution through the TrkB–Akt–PAK5–MAP2–KIF5B pathway and remobilization of syntaphilin-anchored mitochondria. These findings support psilocybin as a mechanistically grounded prophylactic candidate to reduce a major dose-limiting toxicity of cancer therapy.

Heles M, Pasvolsky L, Sathishkumar H et al. · Science (New York, N.Y.) · (2026) · 2 citations · View on PubMed ↗

Tumor-derived antioxidants suppress immunity by depriving T cells of reactive oxygen species.

This study investigated how tumor-derived antioxidants suppress antitumor immunity by depriving T cells of reactive oxygen species (ROS). It found that tumor interstitial fluid has potent antioxidant activity enriched for peroxiredoxin 1 (PRDX1), and that extracellular PRDX1 reduces T cell ROS availability, thereby preventing oxidative inactivation of phosphatases required for T cell receptor-driven signaling. Clinically, it explains why antioxidant approaches can fail or worsen cancer outcomes and identifies PRDX1-mediated ROS deprivation as a potential immunotherapy target.

Wesolowski AJ, Pillay AM, Vardaka P et al. · Science (New York, N.Y.) · (2026) · 1 citations · View on PubMed ↗

Spatiotemporal lineage tracing reveals the dynamic spatial architecture of tumor growth and metastasis.

This study used spatiotemporal lineage tracing combined with high-resolution spatial transcriptomics to map how tumor growth, plasticity, and metastasis co-evolve with the microenvironment in a Kras;Trp53-driven mouse model of lung adenocarcinoma. It found that subclonal expansion drives a hypoxic, immunosuppressive, fibrotic niche associated with emergence of prometastatic cancer cell states, and that tumor phylogeography reveals rewired intercellular interactions in the expanding tumor niche. The approach links dynamic lineage behavior to microenvironment remodeling, offering a framework to understand and potentially target metastatic progression.

Jones MG, Sun D, Min KHJ et al. · Nature genetics · (2026) · View on PubMed ↗

Multi-stromal organoid co-culture modelling reveals epithelial-fibroblast heterogeneity in pancreatic cancer and pancreatitis.

The study compared epithelial–fibroblast interactions and fibroblast diversity in human pancreatic ductal adenocarcinoma (PDAC) versus chronic pancreatitis using human samples, mouse models, and mouse pancreatitis-derived epithelial organoids. It found that co-culture modelling reveals epithelial–stromal heterogeneity, distinguishing fibroblast states and their interaction programs between inflammatory pancreatitis and PDAC. These results support stroma-targeted stratification by defining how specific fibroblast subtypes shape epithelial behavior and potentially treatment response across pancreatic inflammation and cancer.

Li W, Jihad M, Lloyd EG et al. · Nature cell biology · (2026) · View on PubMed ↗ · Free PDF ↗

Surfaceome CRISPR activation screening uncovers ligands regulating tumor sensitivity to NK cell killing.

The study used surfaceome-focused CRISPR activation (CRISPRa) screening to identify cancer cell surface ligands that regulate susceptibility to natural killer (NK) cell killing across human and murine cancer cell lines. It found that the screen recovered known NK-modulating factors (including CD43) and uncovered additional regulators (including CD44 and PDPN) that alter NK cytotoxicity. These findings provide candidate surface targets for engineering or selecting tumors and immunotherapies to improve NK-cell–based cancer treatment.

Dinesh RK, Wang X, Mohammad IA et al. · Nature communications · (2026) · View on PubMed ↗

Vitamin B5 supports anti-PD1 response in HER2-positive gastric cancer and enhances interaction between naïve B cells and T cells.

The study investigated immune remodeling in HER2-positive gastric cancer (HER2+ GC) by performing longitudinal single-cell RNA sequencing with paired TCR/BCR profiling before and after immunochemotherapy (anti–PD-1 plus XELOX/FOLFOX and anti-HER2). It found that pre-treatment HER2+ GC had an immunogenic microenvironment enriched for tumor-reactive T and B cells, and after treatment it showed clonal expansion of tumor-reactive T cells, increased memory B cell differentiation, enhanced naïve B cell recruitment, and increased B–T cell interactions. This suggests vitamin B5–supported anti–PD-1 responsiveness is linked to coordinated adaptive immune activation in HER2+ gastric cancer.

Wang C, Yang J, Lai MY et al. · Nature communications · (2026) · View on PubMed ↗ · Free PDF ↗

Overall survival of immunotherapy versus standard of care in chemorefractory microsatellite stable metastatic colorectal cancer: a propensity score matched analysis of 708 patients.

The study compared overall survival of immune checkpoint inhibitor (ICI)–based regimens versus standard of care in chemorefractory, microsatellite stable metastatic colorectal cancer (pMMR/MSS mCRC) using propensity score matching in 708 patients. It found that after 1:1 matching on age, sex, ECOG performance status, liver metastases, and RAS/BRAF status, ICI-based treatment outcomes could be evaluated against SOC options including trifluridine/tipiracil ± bevacizumab, regorafenib, or fruquintinib. This provides real-world comparative effectiveness evidence for selecting subgroups of pMMR/MSS mCRC patients who may benefit from immunotherapy despite generally limited ICI efficacy.

Vetere G, Osterlund E, Yousef MMG et al. · Journal for immunotherapy of cancer · (2026) · View on PubMed ↗ · Free PDF ↗

Enfortumab vedotin induces immunogenic cell death and shows enhanced preclinical antitumor activity when combined with a PD-1 inhibitor.

This preclinical study investigated how the Nectin-4–directed antibody-drug conjugate enfortumab vedotin induces immunogenic cell death (ICD) and enhances antitumor activity when combined with a PD-1 inhibitor in urothelial cancer models. The key finding was that enfortumab vedotin delivers MMAE to Nectin-4–positive tumor cells, produces bystander killing, and increases activated immune cells in the tumor microenvironment via MMAE-mediated ICD, with improved efficacy when paired with PD-1 blockade. This is significant for immuno-oncology because it provides mechanistic rationale for combining enfortumab vedotin with PD-1 inhibitors to boost durable immune-mediated responses.

Olson DJ, Liu BA, Younan P et al. · Cell reports. Medicine · (2026) · View on PubMed ↗ · Free PDF ↗

Cyclin E-CDK2 regulates cancer cell transcriptional program and response to immunotherapy through BRD4.

This Molecular Cell study examined how cyclin E–CDK2 regulates cancer cell transcription and immunotherapy response through BRD4. The key finding was that CDK2 phosphorylates BRD4 to control its chromatin association, and cyclin E–CDK2 activation represses interferon-stimulated genes, enabling cancer cells to gain resistance to immunotherapy. Scientifically, it identifies a cyclin E–CDK2→BRD4 axis as a transcriptional control point and suggests CDK2 inhibition as a strategy to improve immunotherapy responsiveness.

Chu C, Zheng S, Mitchell N et al. · Molecular cell · (2026) · View on PubMed ↗ · Free PDF ↗

Critical role for the TGF-β1/mTORC1 signaling axis in defining the transcriptional identity of CTHRC1+ pathologic fibroblasts.

This study examined the TGF-β1/mTORC1 signaling axis that shapes the transcriptional identity of CTHRC1+ pathologic fibroblasts in fibrosis, using CRISPR-Cas9 gene editing and transcriptome mapping of TGF-β1-stimulated fibroblasts. It found that more than one-third of TGF-β1-regulated matrisome genes are controlled by mTORC1 and that the TGF-β1 fibroblast transcriptome overlaps with CTHRC1+ fibroblasts seen in idiopathic pulmonary fibrosis (IPF), an overlap that is lost when mTORC1 is disabled. These results support mTORC1 as a key driver of disease-specific fibroblast programs and a potential therapeutic lever to suppress profibrotic ECM remodeling.

Wilson JA, Walters R, Contento G et al. · Science advances · (2026) · View on PubMed ↗ · Free PDF ↗

Functionally active lymphoid aggregates correlate with improved prognosis in brain metastases.

This study analyzed tumor immune microenvironments in more than 200 patients with melanoma brain metastases (BM) or lung adenocarcinoma (LUAD) BM, focusing on B-cell infiltration and the presence of lymphoid aggregates (LAs) and tertiary lymphoid structures (TLS). It found that LAs were associated with increased intratumoral CD8+ T cells in melanoma-BM versus LUAD-BM and that LA presence correlated with improved survival in melanoma-BM but not in LUAD-BM. These findings suggest that functionally active B-cell neighborhood structures may serve as prognostic biomarkers and potentially influence immunotherapy responsiveness in melanoma brain metastases.

Nader NE, Glathar AR, Byrnes EV et al. · Cancer discovery · (2026) · View on PubMed ↗

A phase II multi-institutional single arm trial evaluating TG4010 vaccine plus nivolumab in non-small cell lung cancer.

In a phase II, multi-institutional, single-arm trial (NCT02823990), ICI-naïve non-small cell lung cancer (NSCLC) patients received the MUC1-targeted TG4010 vaccine plus nivolumab to assess safety and anti-tumor activity. The regimen was generally well tolerated, with common adverse events including fatigue (grade 1–3) and injection site reactions (grade 1–2), and the study was terminated early due to slow accrual after enrolling 13 patients. This provides early clinical evidence for combining TG4010 (MUC1 vaccine) with nivolumab in NSCLC, supporting further investigation in adequately powered trials.

Wang CX, Luxardi G, Mori H et al. · Oncoimmunology · (2026) · View on PubMed ↗ · Free PDF ↗

---

Genetics, Genomics & Epigenetics (GWAS/3D epigenome/chromatin/TEs)

Longitudinal dynamics of gene expression and metabolomics in an aging population cohort.

This longitudinal multi-omics study profiled whole-blood gene expression and metabolomics over 8 years in an aging human cohort of 335 females to characterize spatiotemporal molecular dynamics. The key finding was that 5,061 genes and 181 metabolites changed over time, with many individuals showing trajectories that diverged from population-level trends, and that longitudinally variable genes were enriched for aging-relevant pathways including cardiometabolic and neurodegenerative disorders, with trajectories shaped by genetics, circadian rhythm, seasonality, and environmental pollutants. Scientifically, it provides a framework for understanding how aging-associated molecular changes vary within individuals over time.

El-Sayed Moustafa JS, Ramisch A, Raza YN et al. · Science (New York, N.Y.) · (2026) · View on PubMed ↗

Conformational asymmetry of replicated human chromosomes.

This study examined how replication asymmetry affects chromosome organization by analyzing sister chromatid conformation in human cells. Using sister chromatid-sensitive conformation analysis, it found that sister chromatids are consistently misaligned in the 5’→3’ direction of inherited DNA strands, that this persists without cohesin-mediated loop extrusion, and that the misalignment is lost when cohesion is disrupted, with polymer modeling implicating directional misalignment of cohesive cohesins. Scientifically, it reveals a mechanistic link between DNA replication strand orientation and higher-order chromosome architecture.

Corsi F, Steinacker TL, Kolesnikova S et al. · Science (New York, N.Y.) · (2026) · 3 citations · View on PubMed ↗ · Free PDF ↗

Renal Synovial Sarcoma Revisited: Clinicopathologic and Molecular Insights From 70 Cases With Report of a Rare SS18::NEDD4 Fusion.

This multi-institutional case series analyzed 70 cases of primary renal synovial sarcoma to characterize clinicopathologic and molecular features, including a reported rare SS18::NEDD4 fusion. The study compiled comprehensive clinical and histopathologic data and focused on molecular insights from the SS18::NEDD4 fusion. Scientifically, it expands the molecular spectrum of renal synovial sarcoma and supports improved diagnostic recognition of rare fusion-driven disease.

Tan HM, Bayrak BY, Collins K et al. · The American journal of surgical pathology · (2026) · View on PubMed ↗

Sex-specific associations of the plasma-proteome with incident coronary artery disease.

This study integrated genomic and plasma proteomic profiling to assess sex-specific associations with incident coronary artery disease (CAD) in 40,829 UK Biobank participants (55% women; mean age 56.9 years). Over a median 13.7-year follow-up, Cox models across 2,922 plasma proteins identified 440 proteins exclusive to women and 32 exclusive to men associated with incident CAD. These sex-stratified plasma-protein signatures could improve mechanistic understanding and risk prediction for CAD beyond sex-averaged biomarkers.

Sier VQ, Dimitrova K, Peters EHAB et al. · Cardiovascular research · (2026) · 1 citations · View on PubMed ↗ · Free PDF ↗

The Oral Microbiome of King Richard III of England.

This study analyzed the oral microbiome from dental calculus of King Richard III (1452–1485) using shotgun metagenomic sequencing of DNA extracted from three teeth. Nearly 400 million reads were generated, taxonomically profiled, and de novo assembled, with metagenome-assembled genomes used to investigate Tannerella-related signals across ancient and modern comparative datasets. The work provides a high-resolution ancient oral microbiome reference that can inform how oral communities and potential pathogens have shifted from the Neolithic to the present.

Velsko IM, Hübner A, Fagernäs Z et al. · American journal of biological anthropology · (2026) · 2 citations · View on PubMed ↗ · Free PDF ↗

The Evaluation of Molecular Genetics and Clinical Manifestations in Patients With LZTR1-Associated Noonan Syndrome: A Retrospective Chart Review and Review of Literature.

This multi-center retrospective chart review and literature review evaluated molecular genetics and clinical manifestations of LZTR1-associated Noonan syndrome (LZTR1-NS) in patients from three tertiary centers plus 100 additional published individuals (2015–2025). By systematically collecting clinical, molecular, and imaging data and comparing phenotypes by inheritance pattern, the study characterized the LZTR1-NS phenotypic spectrum and genotype–phenotype relationships across autosomal dominant and autosomal recessive inheritance. Defining these patterns can improve diagnostic interpretation and counseling for families with LZTR1 variants.

Jaouadi H, Hicazi Ş, Raski CR et al. · American journal of medical genetics. Part A · (2026) · View on PubMed ↗ · Free PDF ↗

Robust inference and correlates from genetic associations with personality.

The study performed a meta-analysis of genome-wide association studies (GWAS) across 46 cohorts (611,037 to 1.14 million participants) with European-like and African-like genomes to identify robust and generalizable genetic correlates of the Big Five personality traits. It found genetic associations that were robust across cohorts and ancestry-matched analyses, enabling inference of trait correlates and biological/social pathways linked to personality. This improves confidence in polygenic links between DNA and personality and supports more reliable downstream analyses of mechanisms underlying behavioral variation.

Schwaba T, Clapp Sullivan ML, Akingbuwa WA et al. · Nature · (2026) · 1 citations · View on PubMed ↗ · Free PDF ↗

3D epigenome of glial cell types in developing human cortex.

The study mapped the 3D epigenome of human glial cell types during cortical development, focusing on chromatin looping and lineage-associated regulatory architecture. It found that distinct glial cell types exhibit cell-type-specific 3D chromatin organization that underpins differential gene regulation during development. This helps explain how non-coding genetic variants may act through glial-specific regulatory loops to influence neurodevelopmental and neuropsychiatric risk.

Jones IR, Wang L, Kosicki M et al. · Nature · (2026) · View on PubMed ↗ · Free PDF ↗

The moonlighting functions of SEC13 in nonsense-mediated mRNA decay and the regulation of ER stress.

The study examined the moonlighting functions of SEC13 in nonsense-mediated mRNA decay (NMD) and ER stress regulation, building on prior evidence that SEC13 is an ER-localized NMD factor in C. elegans and HeLa cells. It found that SEC13 interacts with core NMD factors and that SEC13 NMD activity can be measured at single-cell resolution in U2OS cells using a newly developed dual-color fluorescent NMD sensor. This clarifies how SEC13 coordinates RNA quality control at the ER and links NMD regulation to broader ER stress control mechanisms.

Monaghan L, Srinath C, Mann AR et al. · RNA (New York, N.Y.) · (2026) · View on PubMed ↗

Tabula Sapiens 2.0: A comprehensive transcriptomic atlas of human cell types.

This Cell study reported Tabula Sapiens 2.0, an expanded human cell transcriptomic atlas built from single-cell RNA-seq data across more organs and tissues. The key finding was that the atlas adds nine new donors (doubling cell counts) and four new tissues, including multi-organ donors that help control for genetic background, age, and epigenetic effects. Scientifically, it provides a richer reference dataset for studying gene regulation, aging, and cell-type specificity of transcription factors.

Cell · (2026) · View on PubMed ↗ · Free PDF ↗

Activation of transposable elements is linked to a region- and cell type-specific interferon response in Parkinson’s disease.

This study investigated whether transposable element (TE) activation contributes to Parkinson’s disease neuroinflammation by analyzing bulk and single-nuclei RNA-seq from postmortem brain tissue across four regions. It found that over a thousand TEs (including LINE-1 elements and ERVs) are expressed in a region- and cell type-specific manner, with increased TE expression in microglia and neurons in the substantia nigra and putamen in PD. These results suggest that TE derepression may be linked to interferon responses and could represent a mechanistic driver of PD-associated neuroinflammation.

Garza R, Adami A, Thiruvalluvan A et al. · Science advances · (2026) · View on PubMed ↗ · Free PDF ↗

Epstein-Barr virus-associated chromatin activation and enhancer engagement in T/NK-cell lymphoproliferative diseases.

The study investigated EBV-associated chromatin activation and enhancer engagement in primary T cells, NK cells, EBV-positive T/NK-cell lymphoproliferative disease cell lines, virus-negative controls, and clinical chronic active EBV disease samples. Using genome-wide and single-cell multiome analyses, the authors mapped 3D chromatin organization, histone modifications, viral–host chromatin proximity, regulatory element activity, and linked these to EBV-driven transcriptional programs. These findings support a non-genetic, virus-driven epigenetic mechanism for aggressive EBV-associated T/NK-cell lymphoproliferative diseases and suggest chromatin/ enhancer targets as potential biomarkers or therapies.

Isogai S, Okabe A, Tanaka K et al. · Blood · (2026) · View on PubMed ↗ · Free PDF ↗

Global, Regional, and National Burden of Myocarditis and Its Impairment, 1990-2023.

This Global Burden of Disease (GBD) 2023 analysis estimated global, regional, and national myocarditis prevalence, incidence, disability-adjusted life years (DALYs), and mortality from 1990 to 2023 using administrative health facility and vital registration data stratified by age, sex, and Socio-demographic Index (SDI) quintiles. It quantified how myocarditis burden and mortality-to-incidence ratio (MIR) have changed over time across countries and demographic groups. These results provide a comprehensive epidemiologic baseline to guide prevention and resource allocation for myocarditis worldwide.

Journal of the American College of Cardiology · (2026) · View on PubMed ↗

---

Developmental Biology & Plant Biology (embryogenesis/cell polarity/cytoskeleton)

An embryo-derived peptide signal directs endosperm polarity in Arabidopsis.

This study investigated how an embryo-derived peptide signal establishes endosperm polarity during Arabidopsis seed development. It found that the receptor kinase HAIKU2 (IKU2) works with the transcription factor WRKY10/MINISEED3 (MINI3) to ensure robust endosperm polarity by regulating homeodomain transcription factors WOX8 and WOX9, linking egg cell fertilization–dependent signaling to polarized endosperm organization. These results clarify the molecular pathway that coordinates embryo-to-endosperm communication to enable proper nutrient transfer and seed formation.

Creff A, Rhodes J, Salaün C et al. · Science (New York, N.Y.) · (2026) · View on PubMed ↗ · Free PDF ↗

A single-point mutation in TRPA1 drives heat resilience in oviparous embryos.

This study used a comparative functional approach to show that a single-point mutation in the pore domain of the ion channel TRPA1 drives heat resilience in oviparous embryos. Blocking heat-activated TRPA1 in oviparous embryos impaired dorsal-root-ganglion axon growth, disrupted myelination, and caused limb weakness at hatching, linking TRPA1 heat sensing to developmental thermotolerance. The findings are significant for understanding how specific TRPA1 sequence changes enable species-specific thermal adaptation during embryogenesis.

Feng TY, Dong W, Zheng D et al. · Science advances · (2026) · View on PubMed ↗ · Free PDF ↗

A MAP-SNARE interaction links cortical microtubules to the exocytic fusion machinery during auxin-dependent growth remodeling.

This study investigated how cortical microtubules interface with plasma-membrane vesicle fusion machinery during auxin-dependent apical hook opening in Arabidopsis, focusing on the microtubule-associated protein WDL4 and the Qa-SNARE SYP121. WDL4 was found to physically interact with SYP121 and act as a molecular bridge linking cortical microtubules to PM-associated SNARE-mediated exocytic fusion during auxin-driven growth remodeling. This mechanistic MAP–SNARE coupling provides a concrete targetable pathway for how plant cells coordinate cytoskeletal positioning with hormone-regulated membrane trafficking.

Deng J, Qin J, Wang P et al. · Science advances · (2026) · View on PubMed ↗ · Free PDF ↗

Cell body position of Drosophila Moonwalker Descending Neurons regulates locomotor circuit function.

This study investigated how neuronal cell body position affects circuit function in Drosophila by analyzing the adult Moonwalker Descending Neurons (MDNs) that command backward locomotion. It found that MDNs must maintain cell body contact to initiate backward walking, with the transcription factor Hunchback driving expression of the adhesion molecule Lar and its ligand Dlp to promote MDN clustering that blocks backward initiation. These results establish cell-body positioning and adhesion-driven clustering as a functional control layer for locomotor circuit output.

Lee K, Graciani J, Carvajal NR et al. · Proceedings of the National Academy of Sciences of the United States of America · (2026) · View on PubMed ↗

---

Targeted Oncology (Small Molecules/ADCs/RAS/BTK/CDK/Other Targets)

Neoadjuvant Anbenitamab and HB1801 in ERBB2-Positive Breast Cancer: A Phase 3 Randomized Clinical Trial.

This phase 3 randomized clinical trial studied neoadjuvant anbenitamab (an ERBB2-biparatopic antibody) plus HB1801 (solvent-free albumin-bound docetaxel) in patients with early ERBB2-positive breast cancer. The study evaluated whether adding anbenitamab to HB1801 could improve efficacy without increasing toxicity compared with standard neoadjuvant ERBB2-targeted regimens. If positive, this would support a receptor-clustering ERBB2 antibody strategy combined with albumin-bound taxane chemotherapy as an improved neoadjuvant option for ERBB2-positive early breast cancer.

Li J, Liu T, Yu KD et al. · JAMA oncology · (2026) · View on PubMed ↗ · Free PDF ↗

Exposure-response and dose simulation of belantamab mafodotin in combination with standards of care in patients with relapsed/refractory multiple myeloma.

This analysis performed exposure-response and dose simulation to characterize belantamab mafodotin pharmacology when combined with standard-of-care regimens in patients with relapsed/refractory multiple myeloma (RRMM). Using Cycle 1 exposure data from DREAMM-6/7/8 and simulated BVd dosing, the study aimed to support benefit-risk optimization of belantamab mafodotin dosing strategies to improve outcomes while managing ocular toxicity. Scientifically and clinically, it provides a quantitative framework to refine dosing for antibody-drug conjugate therapy in RRMM.

Lonial S, Richardson PG, Ferron-Brady G et al. · Haematologica · (2026) · View on PubMed ↗ · Free PDF ↗

CDK12/13 inhibition overcomes platinum resistance by impairing RNA metabolism.

The study tested whether pharmacological inhibition of CDK12 and CDK13 (CDK12/13 inhibition) can overcome platinum resistance in epithelial ovarian cancer (EOC) models, including both platinum-sensitive and platinum-resistant settings. It found that CDK12/13 inhibition synergized with platinum to enhance cytotoxicity, delayed platinum-resistant recurrence in vitro and in vivo, and revealed a vulnerability where acquired resistance to CDK12/13 inhibition increased platinum sensitivity. This supports CDK12/13 inhibition as a mechanistically grounded combination strategy targeting RNA metabolism to treat platinum-resistant EOC.

Pellarin I, Rossi V, Margiotta RG et al. · Signal transduction and targeted therapy · (2026) · View on PubMed ↗ · Free PDF ↗

Broad baseline-variable profiling of visceral conversion in bone-only HR+/HER2 - metastatic breast cancer treated with CDK4/6 inhibitors.

This multicentre retrospective cohort study evaluated visceral conversion in 692 patients with bone-only HR+/HER2− metastatic breast cancer treated with the CDK4/6 inhibitors palbociclib, ribociclib, or abemaciclib plus endocrine therapy across 24 Italian centres. Using a competing-risks framework, the study quantified visceral conversion and identified reproducible baseline correlates from a 35-variable candidate set. Clinically, these baseline predictors could help stratify patients at risk of visceral progression during CDK4/6 inhibitor therapy and guide monitoring and treatment decisions.

Scafetta R, Troiano R, Guarino A et al. · European journal of cancer (Oxford, England : 1990) · (2026) · View on PubMed ↗ · Free PDF ↗

Daraxonrasib for Previously Treated RAS-Mutant Non-Small-Cell Lung Cancer.

This phase 1–2 multicenter dose-escalation/dose-expansion trial studied daraxonrasib (RMC-6236), an oral RAS(ON) multiselective tri-complex inhibitor of GTP-bound mutant and wild-type RAS isoforms, in previously treated patients with advanced RAS-mutant non-small-cell lung cancer. The trial assessed safety as the primary endpoint and evaluated antitumor activity as secondary outcomes across multiple daraxonrasib dose levels. If effective and tolerable, daraxonrasib could provide a new targeted option for RAS-mutant NSCLC after prior therapy.

Arbour KC, Punekar S, Luo J et al. · The New England journal of medicine · (2026) · 1 citations · View on PubMed ↗

Changes in the transcriptome and synthetic lethal dependencies following KRAS mutant expression reveal profound tissue specificity.

This study investigated why oncogenic KRAS mutations show tissue-restricted tropism by generating endogenous conditional KRAS-mutant isogenic cell lines across permissive lineages (lung, colon, pancreas) and a nonpermissive breast lineage using CRISPR-mediated genome engineering. It found that KRAS mutant expression produces profound, lineage-specific changes in the transcriptome and reveals tissue-specific synthetic lethal dependencies via integrated CRISPR fitness screens and comparative transcriptomics. This provides a rationale for tailoring KRAS-targeted combination therapies to the tissue context where KRAS-driven transformation is permissive.

Martin TD, Choi MY, McBride JC et al. · Proceedings of the National Academy of Sciences of the United States of America · (2026) · View on PubMed ↗ · Free PDF ↗

Real-world outcomes of datopotamab deruxtecan after trastuzumab deruxtecan in hormone receptor-positive, HER2-negative metastatic breast cancer.

This single-center retrospective study evaluated real-world outcomes of datopotamab deruxtecan (Dato-DXd) after prior trastuzumab deruxtecan (T-DXd) in hormone receptor-positive, HER2-negative metastatic breast cancer patients. The key finding was the clinical activity and disease control of Dato-DXd stratified by whether patients had been exposed to T-DXd, using endpoints such as disease control rate and objective response rate. These data inform practical sequencing of antibody-drug conjugates in a setting where optimal post–T-DXd strategies are not well established.

Aoyama Y, Ozaki Y, Kuno M et al. · Breast cancer (Tokyo, Japan) · (2026) · View on PubMed ↗ · Free PDF ↗

---

Cancer Vaccines & Immuno-Cell Therapies (CAR-T/MAIT/Prevention)

Bicistronic CD19/CD22 CAR T-Cell Therapy in Pediatric B-Cell Acute Lymphoblastic Leukemia: A Nonrandomized Clinical Trial.

This open-label, multicenter phase 2 nonrandomized trial evaluated bicistronic CD19/CD22 CAR T-cell therapy in pediatric patients with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL). The key aim was to determine safety and efficacy of dual-targeting to reduce antigen-loss relapse and improve remission durability. Clinically, successful results would strengthen the rationale for bicistronic CD19/CD22 CAR designs to improve long-term outcomes in high-risk pediatric B-ALL.

Wan X, Tang Y, Cai J et al. · JAMA oncology · (2026) · View on PubMed ↗

Adoptive MAIT cell therapy for liver cancer enhanced by multimodal modulation of immune receptors and checkpoints.

This Med (New York) study evaluated adoptive MAIT cell therapy for liver cancer by profiling MAIT cells from peripheral blood of healthy donors and hepatocellular carcinoma patients and then engineering therapy using multimodal modulation of immune receptors and checkpoints. The key finding was that MAIT cells show disease-associated phenotypic alterations characterized by immune checkpoint dysregulation in hepatocellular carcinoma, and that therapeutic receptor/checkpoint modulation enhanced MAIT antitumor potential. Clinically, it supports a strategy to improve MAIT cell efficacy in liver cancer by combining adoptive transfer with targeted immune receptor and checkpoint tuning.

Li YR, Shen X, Zhu Y et al. · Med (New York, N.Y.) · (2026) · View on PubMed ↗ · Free PDF ↗

Breast cancer prevention by prophylactic Lalba mRNA-LNP vaccination.

This study tested whether prophylactic vaccination with lipid nanoparticle (LNP)-encapsulated mRNA encoding alpha-lactalbumin (LALBA; LALBA protein expressed by mammary luminal progenitors) can prevent breast cancer, as an interceptive immunotherapy strategy. The key finding is that prophylactic LALBA mRNA-LNP vaccination can induce tumor-suppressive immune responses that reduce breast cancer development compared with controls. This supports a cell-of-origin–directed vaccine concept for early-stage cancer prevention by priming immunity before malignant progression.

Nishida J, Seehawer M, Rojas Jimenez E et al. · Proceedings of the National Academy of Sciences of the United States of America · (2026) · View on PubMed ↗ · Free PDF ↗

---

Ophthalmology (Retina/Uveitis/Glaucoma/AMD/Ocular toxoplasmosis)

PEBP1 Regulates Ferroptosis in Acute Glaucoma: Targeted Therapy Using Engineered Exosomes.

This study investigated PEBP1 as a regulator of ferroptosis in acute glaucoma using rat retinal models across acute, subacute, and chronic phases of pathological high intraocular pressure (ph-IOP), integrating single-cell RNA sequencing and spatial transcriptomics. The work used engineered exosomes to deliver targeted therapy linked to PEBP1-mediated ferroptosis pathways to counter retinal ganglion cell degeneration. Scientifically, it identifies a potentially actionable ferroptosis control node (PEBP1) and provides a faster-acting exosome delivery approach relevant to the acute clinical timeline of glaucoma.

Huang Y, Gong D, Guo J et al. · FASEB journal : official publication of the Federation of American Societies for Experimental Biology · (2026) · View on PubMed ↗ · Free PDF ↗

Evidence and Consensus Based Imaging Guidelines in Ocular Toxoplasmosis. Multimodal imaging in Uveitis (MUV) Taskforce Report 14.

This international MUV taskforce study developed imaging and consensus-based guidelines for ocular toxoplasmosis (OT) using an expert nominal group technique (NGT) informed by a systematic literature review and multimodal datasets from uveitis specialists and retina experts. The key output was consensus recommendations specifying how to apply multimodal imaging (including color fundus photography and optical coherence tomography) in OT cases meeting Standardized Uveitis Nomenclature (SUN) criteria. These guidelines standardize OT imaging workflows across centers, improving comparability of clinical findings and supporting more consistent diagnosis and monitoring in uveitis practice.

Trinco A, Invernizzi A, de-la-Torre A et al. · Ophthalmology. Retina · (2026) · View on PubMed ↗ · Free PDF ↗

Pulmonary Nodules.

This narrative clinical review summarizes how pulmonary nodules are classified (solid vs subsolid, including part-solid and pure ground-glass) and how imaging follow-up and malignancy risk assessment are used in practice. It emphasizes that stability for 2 years generally supports benignity for solid nodules, whereas subsolid nodules require longer stability, and that CT surveillance and risk prediction models guide management. Scientifically and clinically, the review provides an evidence-based framework for selecting surveillance versus further diagnostic evaluation based on nodule type and imaging trajectory.

Callister MEJ, Silvestri GA · The New England journal of medicine · (2026) · View on PubMed ↗

Elevated translocator protein in skull bone marrow is linked to human chronic pain.

This study assessed whether translocator protein (TSPO; 18-kDa) is elevated in skull bone marrow (SBM) in humans with chronic pain using integrated PET/MRI in cohorts with chronic low back pain (cLBP, n=88), knee osteoarthritis (KOA, n=37), and healthy controls (n=22). It found that TSPO levels were higher in SBM of chronic pain patients (n=125 total) than in controls, with spatially partially segregated patterns and associations with pain and pain-comorbid symptoms. The results implicate immune-cell density or neuroimmune activation in SBM as a potential biomarker and mechanistic contributor to chronic pain.

Mohammadian M, Efthimiou N, Gabriel K et al. · Science translational medicine · (2026) · 1 citations · View on PubMed ↗ · Free PDF ↗

Genetic evidence and cross-species functional characterization implicate CNN2 in age-related macular degeneration susceptibility.

This study integrated AMD genome-wide association study (GWAS) data with expression quantitative trait locus (eQTL) prioritization and then used in vivo zebrafish screening followed by mouse modeling to test candidate genes for age-related macular degeneration (AMD) susceptibility, implicating CNN2. It found that downregulation of cnn2 (and sarm1) in zebrafish causes ocular structural abnormalities and visual functional impairment, and that mouse Cnn2 deficiency disrupts photoreceptor structure. This cross-species genetic and functional evidence implicates CNN2 as a causal AMD susceptibility gene and highlights photoreceptor integrity as a downstream disease-relevant phenotype.

Cheng FF, Mou H, Liu Z et al. · Proceedings of the National Academy of Sciences of the United States of America · (2026) · View on PubMed ↗ · Free PDF ↗

Aflibercept 8 mg for diabetic macular edema and neovascular age-related macular degeneration: an italian expert consensus paper.

This Italian expert consensus paper studied real-world clinical recommendations for using aflibercept 8 mg in neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). Using a modified Delphi process with ophthalmologists from specialized centers, the authors reached consensus statements on clinical use and implementation feasibility. The guidance is intended to standardize aflibercept 8 mg practice in Italy and support consistent management of these major retinal diseases.

Bandello F, Borrelli E, De Falco S et al. · Graefe’s archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · (2026) · View on PubMed ↗ · Free PDF ↗

---

Hematologic Malignancies (AML/MCL/MM/ALL/HSCT/MRD)

Measurable residual KMT2A partial tandem duplication before allogeneic stem cell transplantation in acute myeloid leukemia.

This retrospective cohort study assessed whether KMT2A partial tandem duplication (KMT2A-PTD) measurable residual disease (MRD) measured by real-time quantitative PCR predicts outcomes before allogeneic stem cell transplantation (allo-HSCT) in 180 patients with AML. Pre-transplant MRD positivity (≥1500 copies/10^5 ABL1) was quantified and compared between MRD-positive and MRD-negative groups to evaluate prognostic impact. If validated, pre-allo-HSCT KMT2A-PTD MRD could refine risk stratification and guide post-transplant management in KMT2A-PTD AML.

Wang L, Fu H, Qin Y et al. · Haematologica · (2026) · View on PubMed ↗ · Free PDF ↗

Efficacy and safety of bridging therapy prior to CAR T-cell therapy in relapsed or refractory multiple myeloma.

This multicenter real-world cohort study evaluated the efficacy and safety of bridging therapy before BCMA-directed CAR T-cell therapy in 399 patients with relapsed or refractory multiple myeloma (RRMM), including 348 who received bridging therapy. Bridging therapy recipients had more advanced and adverse disease biology (e.g., higher high-risk cytogenetics and penta-class refractoriness), and bridging efficacy varied across subgroups. Clinically, these findings help contextualize how bridging therapy influences outcomes in BCMA CAR T-cell pathways when baseline disease risk is higher.

Wesener MC, Demel UM, Pabst T et al. · Haematologica · (2026) · View on PubMed ↗ · Free PDF ↗

Gilteritinib plus azacitidine in patients with newly diagnosed FLT3 mutation-positive acute myeloid leukemia who were ineligible for intensive chemotherapy: final results of the phase III LACEWING study.

The phase 3 LACEWING study evaluated gilteritinib plus azacitidine (GIL+AZA) versus gilteritinib alone (GIL) and azacitidine alone (AZA) in newly diagnosed FLT3 mutation-positive AML patients ineligible for intensive chemotherapy. Final 6.5-year outcomes reported overall survival comparisons across arms and included additional subgroup, measurable residual disease (MRD), and pharmacokinetic analyses. Clinically, the long-term results inform the optimal frontline regimen for FLT3-mutated AML patients who cannot receive intensive induction.

Wang ES, Montesinos P, Minden MD et al. · Haematologica · (2026) · View on PubMed ↗ · Free PDF ↗

Comparative Efficacy of BTK Inhibitors in Treatment-Naïve and Relapsed/Refractory Mantle Cell Lymphoma: A Systematic Review and Meta-Analysis.

This systematic review and meta-analysis compared the efficacy of Bruton tyrosine kinase inhibitors—ibrutinib, zanubrutinib, and acalabrutinib—in treatment-naïve versus relapsed/refractory mantle cell lymphoma (MCL). Across 70 included studies (RCTs and single-arm), the pooled complete response (CR) rate was higher in the treatment-naïve group than in the relapsed/refractory group (76.5% vs 43.2%), with regimen-specific differences reported for zanubrutinib-containing approaches. These comparative efficacy estimates can guide selection of BTK inhibitors by disease setting (TN vs R/R) in clinical decision-making for MCL.

Xu F, Zou X, Yang Y et al. · Journal of cellular and molecular medicine · (2026) · View on PubMed ↗ · Free PDF ↗

High time for risk-adapted treatment in mantle cell lymphoma.

This Lancet Haematology perspective evaluated risk-adapted treatment strategies in mantle cell lymphoma by focusing on biological predictors rather than age-based selection. It highlights that TP53 mutations or deletions, blastoid histology, and high Ki-67 proliferation index consistently identify patients at high risk of relapse, with positive measurable residual disease (MRD) serving as a strong surrogate endpoint. Scientifically and clinically, the article argues for shifting treatment intensity and targeted approaches toward biology- and MRD-guided decision-making to reduce toxicity while improving outcomes.

Glimelius I, Nikkarinen A, Meriranta L et al. · The Lancet. Haematology · (2026) · View on PubMed ↗

Teclistamab and Daratumumab Immune-Based Doublet Therapy for Relapsed/Refractory Multiple Myeloma: the TRIMM-2 Study.

This phase 1b TRIMM-2 study investigated the safety and efficacy of immune-based doublet therapy combining teclistamab (BCMA×CD3 bispecific) with daratumumab (anti-CD38) in patients with relapsed/refractory multiple myeloma (RRMM). The key finding was the trial’s assessment of safety as the primary endpoint and overall response as a secondary endpoint in triple-class–exposed RRMM, with eligibility including ≥3 prior lines of therapy or double-refractory status to a proteasome inhibitor and immunomodulatory drug. The results are significant because they test a rational combination of two antibody-based mechanisms to improve outcomes in heavily pretreated RRMM while characterizing tolerability.

Rodriguez-Otero P, Morillo D, D’Souza A et al. · Blood advances · (2026) · View on PubMed ↗ · Free PDF ↗

Azacitidine-Venetoclax or Induction Chemotherapy for Acute Myeloid Leukemia.

This multicenter phase 2 randomized trial compared azacitidine plus venetoclax versus standard induction chemotherapy in previously untreated adults with acute myeloid leukemia who were eligible for induction therapy. The study evaluated outcomes including efficacy and safety between the hypomethylating-venetoclax regimen and induction chemotherapy. The results are clinically significant because they directly inform first-line treatment selection for fit AML patients who may benefit from less intensive therapy.

Fathi AT, Perl AE, Fell GG et al. · The New England journal of medicine · (2026) · 1 citations · View on PubMed ↗

---

Cardiometabolic Health & Obesity Pharmacotherapy

Cross-Sectional and Longitudinal Association Between Biological Aging Acceleration and the Risk of Osteoarthritis: A Cohort Study From UK Biobank.

This UK Biobank cohort study examined associations between biological aging acceleration and osteoarthritis (OA) risk using phenotypic age (PhenoAge) and Klemera-Doubal age (KDMAge) in 332,261 participants. Biological aging acceleration—computed as residuals from regressing KDMAge and PhenoAge on chronological age—was tested for relationships with OA prevalence and incidence using logistic and Cox regression. If confirmed, biological aging metrics could serve as risk biomarkers for OA beyond chronological age.

Liu S, Wang W, Li C et al. · International journal of rheumatic diseases · (2026) · View on PubMed ↗

Postmarketing Safety Signals and Medication-Use Risks of GLP-1-Based Therapies in Diabetes and Obesity: A Multi-Source Pharmacovigilance and Regulatory Evidence-Mapping Study.

This multi-source pharmacovigilance and regulatory evidence-mapping study characterized postmarketing safety signals and medication-use risks of GLP-1-based therapies, including GLP-1 receptor agonists and the GIP/GLP-1 co-agonist tirzepatide, in diabetes and obesity care. Using FDA Adverse Event Reporting System (FAERS) data from 2021Q1–2026Q1 with deduplication and analysis at the primary-suspect product level, it assessed safety signals across semaglutide, tirzepatide, dulaglutide, liraglutide, exenatide, and lixisenatide. Clinically, the results aim to improve postmarketing risk detection and regulatory decision-making for widely used incretin-based drugs.

Ren L, Zhang Y, Fang F et al. · Diabetes, obesity & metabolism · (2026) · View on PubMed ↗ · Free PDF ↗

Molecular mechanisms and pathogenesis of MASH.

This article synthesized current knowledge on the molecular mechanisms and pathogenesis of metabolic dysfunction-associated steatohepatitis (MASH), the progressive form of MASLD. It frames MASH as a multi-organ disease driven by metabolic syndrome and highlights its role as a major risk factor for fibrosis, cirrhosis, and hepatocellular carcinoma (HCC). Clarifying mechanisms underlying MASH pathogenesis supports identification of therapeutic targets and risk stratification strategies for a growing global liver disease burden.

Gallage S, Govaere O, Anstee QM et al. · Nature · (2026) · View on PubMed ↗

Current therapeutic landscape and future treatment perspectives of MASH.

This review summarized the current therapeutic landscape and future treatment perspectives for MASH, emphasizing its heterogeneity and systemic complications beyond liver disease. It highlights an inflection point in late-stage trials with accelerated approval of the thyroid hormone receptor-β (THRβ) agonist resmetirom and the GLP-1 receptor agonist semaglutide. These developments suggest expanding pharmacologic options for MASH while motivating next-generation strategies to address residual risk and extrahepatic outcomes.

Gallage S, Govaere O, Anstee QM et al. · Nature · (2026) · View on PubMed ↗

Late-life semaglutide treatment slows ageing and extends lifespan in female mice.

The study tested whether late-life treatment with the GLP-1 receptor agonist semaglutide affects ageing and lifespan in 20-month-old female C57BL/6 mice using physiological assessments, nutrient-sensing pathway analyses, and lifespan follow-up. It found that 3 months of semaglutide improved physiological function, attenuated hallmarks of ageing, modulated nutrient sensors, conserved genetic regulators of ageing, and that continued treatment extended lifespan. This supports semaglutide as a candidate geroprotective intervention with mechanisms overlapping calorie restriction.

Feng Y, Barthez M, Wang Y et al. · Nature · (2026) · 2 citations · View on PubMed ↗ · Free PDF ↗

Study of weight loss intervention to find an effective strategy for obesity management and the TARGET of weight loss amount for reducing health disorders (SLIM-TARGET): a randomized controlled trial.

The study conducted the SLIM-TARGET randomized controlled trial to determine effective 12-month weight-loss targets for improving obesity-related disorders in adults with overweight or obesity and multiple obesity-related conditions. It assigned 294 participants to standard treatment (≥3% weight loss target) versus intensive treatment (≥7% target) including frequent nutritional guidance, enhanced diet/exercise therapy, and additional pharmacotherapy, with the primary endpoint defined as weight loss plus improvement in at least two obesity-related disorders at 12 months. The results are intended to define clinically actionable weight-loss thresholds for reducing obesity-related health disorders.

Koshizaka M, Yokoh H, Ishikawa K et al. · Endocrine journal · (2026) · View on PubMed ↗ · Free PDF ↗

Intervention Strategies for Preventing Knee Osteoarthritis: A Systematic Review.

The study systematically reviewed randomized controlled trials to evaluate intervention strategies for primary and secondary prevention of knee osteoarthritis (OA) in at-risk populations or people with knee OA. It searched major databases (MEDLINE, EMBASE, CINAHL, PEDro, and Cochrane Library) through June 10, 2025 and included RCTs assessing prevention interventions with outcomes not pre-specified in the abstract. This synthesis aims to identify evidence-based strategies to reduce incidence or progression of knee OA.

Almeida Silva HJ, Perea J, Dantas G et al. · JOSPT open · (2026) · View on PubMed ↗ · Free PDF ↗

Where the Future Lies: GLP-1 Receptor Agonists as Therapeutics for Dermatologic Comorbidities.

This review article examined emerging clinical and real-world evidence on glucagon-like peptide-1 receptor agonists (GLP-1RAs) as therapies for dermatologic comorbidities in populations with chronic inflammatory skin diseases such as psoriasis and hidradenitis suppurativa. The key finding is that GLP-1RAs may improve dermatologic outcomes while also reducing metabolic comorbidity burden (e.g., obesity/insulin resistance) that commonly coexists with these conditions. Clinically, this supports considering GLP-1RAs as immunometabolic adjuncts in dermatology, potentially addressing both skin disease and cardiometabolic risk.

DeCoster M, Narla S · Clinics in dermatology · (2026) · View on PubMed ↗

The multiple composite risk index estimates the risks of sarcopenia and comorbidities: unveiling the role of oxidative balance score.

This study used two nationally representative datasets (CHARLS and NHANES) to develop and validate a multiple composite risk index, UHR-BRI (uric acid to HDL cholesterol ratio combined with body roundness index), for predicting sarcopenia and related comorbidities. It found that the UHR-BRI index was associated with higher risks of sarcopenia and comorbidity burden, supporting oxidative-balance-related risk stratification. Scientifically and clinically, the index could help identify older adults at elevated sarcopenia risk using routinely available biomarkers and anthropometric measures.

Liu M, Chu X, Zeng D et al. · Annals of medicine · (2026) · View on PubMed ↗ · Free PDF ↗

Pharmacological management of obesity: Current landscape and emerging therapies.

This narrative review summarized the current pharmacological management landscape for obesity and highlighted emerging therapies, focusing on major approved drugs and their mechanisms. It reported that modern obesity pharmacotherapy includes six widely used approved agents—Orlistat, Phentermine/Topiramate, Naltrexone/Bupropion, Liraglutide, Semaglutide, and Tirzepatide—after earlier monoaminergic drugs were withdrawn for safety concerns. The review is clinically significant because it consolidates evidence-based options for chronic obesity treatment and frames where newer therapies may expand care.

Atal S, Agrawal C, Gupta R et al. · Indian journal of pharmacology · (2026) · View on PubMed ↗

---

Infectious Disease Mechanisms & Antivirals (including TB/MPXV/Influenza PA-X)

Mechanism of the M. tuberculosis DprE1-DprE2 epimerase complex and inhibition by anti-tubercular drugs.

This mechanistic study investigated the Mycobacterium tuberculosis DprE1–DprE2 epimerase complex and how anti-tubercular drugs inhibit it. Using cryo-EM structures of the DprE1–DprE2 complex bound to substrate or quabodepistat (DprE1) and to activated pretomanid or delamanid (DprE2), the authors defined how the membrane-associated tetrameric assembly and drug binding relate to inhibition. These structural insights can inform rational development and optimization of DprE1/DprE2-targeting tuberculosis therapeutics.

Gao S, Wu F, Zhang Y et al. · Nature chemical biology · (2026) · View on PubMed ↗

Structure and operating principles of a monkeypox virus replisome.

The study determined the structure and assembly principles of the monkeypox virus (MPXV) replisome by characterizing how the MPXV polymerase subunits (F8 with processivity factors A22 and E4) coordinate with the hexameric helicase-primase (E5). It found structural/functional operating principles explaining how E5 transitions from an autoinhibited, weak-helicase state to productive replication when coupled to the polymerase. This provides a mechanistic framework for antiviral strategies targeting MPXV DNA replication machinery.

Yu Z, Sathyanarayana P, Tan JMJ et al. · Nature · (2026) · View on PubMed ↗ · Free PDF ↗

An endonuclease inhibitor unlocks the PA-X shutoff mechanism in influenza A virus.

This work studied the influenza A virus PA-X host-shutoff mechanism, focusing on how PA-X’s C-terminal basic-rich region controls self-mRNA cleavage, using biochemical assays with an endonuclease inhibitor to suppress PA-X activity. The authors found that PA-X directly binds RNA via its C-terminal region and induces broad mRNA degradation with minimal sequence specificity, while viral RNAs are protected from degradation. Unlocking PA-X expression enabled mechanistic characterization and advances understanding of how influenza evades host translation and regulates viral gene expression.

Oishi K, Sano K, Yamayoshi S et al. · Cell reports · (2026) · View on PubMed ↗ · Free PDF ↗

---

Inflammation, Immunity & Host Defense (NETs, macrophage chimeric mRNAs, bacterial defense)

Functional chimeric mRNAs encode proteins in mammalian immunity.

The study investigated whether distant mammalian mRNAs can undergo trans-splicing to form functional chimeric transcripts in macrophages, using a pipeline that combined long-read direct RNA sequencing with targeted and non-targeted validation. It found that inflammation induces interchromosomal DNA interactions that position parent genes to enable formation of protein-coding chimeric mRNAs. This provides a mechanistic route for generating immune-relevant protein diversity during inflammation and suggests a new layer of post-transcriptional regulation in mammalian immunity.

Venezia O, Kane H, Du G et al. · Nature · (2026) · View on PubMed ↗ · Free PDF ↗

Dual sensing activates antiviral reverse transcriptase for membrane targeting.

This Cell Host & Microbe study investigated activation mechanisms of the prokaryotic type 2 defense-associated reverse transcriptase (DRT2) system in bacteria. The key finding was that DRT2 activation can occur via two distinct inputs—direct binding by a phage-encoded single-stranded DNA-binding protein (SSB/SSAP) or sensing elevated intracellular dGTP levels driven by the phage ribonucleotide reductase NrdAB—followed by Neo effector production that targets the bacterial membrane. This is significant because it clarifies how phage-triggered sensing activates antiviral reverse transcription and membrane disruption, informing broader understanding of bacterial defense systems.

Xia Y, Qi H, Wei XY et al. · Cell host & microbe · (2026) · View on PubMed ↗

M-SYFSF attenuates diabetic kidney disease by suppressing Piezo1-associated cGAS-STING signalling and tubular pyroptosis.

This preclinical study tested whether the modified Shen-Yan-Fang-Shuai formula (M-SYFSF) protects against diabetic kidney disease in rats and investigated its mechanistic effects on Piezo1-mediated Ca2+ signalling, cGAS-STING activation, and tubular pyroptosis. M-SYFSF attenuated DKD and suppressed the Piezo1-associated cGAS-STING pathway linked to tubular pyroptotic injury. These findings support M-SYFSF as a potential therapeutic strategy targeting mechanotransduction–innate immune crosstalk in DKD.

Li Y, Hou J, Wu X et al. · Phytomedicine : international journal of phytotherapy and phytopharmacology · (2026) · View on PubMed ↗

Sequential clearance of neutrophil extracellular traps for precision therapy of sepsis.

This study investigated a therapeutic strategy for sepsis by targeting neutrophil extracellular traps (NETs) using a “sequential NETs-clearance” approach that both inhibits NET overproduction and promotes capture/degradation. The key finding is that engineered multifunctional materials can coordinate NET suppression with targeted clearance to precisely mitigate NET-associated sepsis pathologies. This provides a translational framework for improving NET-directed therapy beyond approaches that only block formation or only degrade NETs.

Wang N, Jin Y, Song J et al. · Science advances · (2026) · View on PubMed ↗ · Free PDF ↗

MicroRNA-224 orchestrates BMP and TGFβ signaling and is a therapeutic target in preclinical pulmonary arterial hypertension.

This study investigated how microRNA-224-5p (miR-224) regulates BMP and TGFβ signaling and whether it is a therapeutic target in preclinical pulmonary arterial hypertension (PAH), using patient samples and multiple pulmonary hypertension models (mouse, rat, pig) plus pulmonary arterial smooth muscle cells (PASMCs). It found that miR-224 is upregulated in PAH across models and delineated a mechanism in which miR-224 orchestrates BMP/TGFβ pathway activity to drive pulmonary vascular remodeling. This positions miR-224 as a mechanistically grounded target for PAH therapy aimed at upstream control of pro-remodeling signaling networks.

Bikou O, Halouani A, Sun Y et al. · Science translational medicine · (2026) · View on PubMed ↗

Sustained neutrophil extracellular traps cause fracture nonunion.

This study examined the role of neutrophil extracellular traps (NETs) in fracture healing and their association with nonunion in both mice and humans, focusing on NET clearance pathways. It found that injury triggers rapid but transient NET formation, and that combined genetic deletion of DNase1 and DNase1-like-3 initially favors early callus mineralization but sustained NETs promote fracture nonunion. These findings identify NET persistence and impaired NET clearance as causal contributors to nonunion and suggest DNase-based or NET-modulating strategies to improve healing outcomes.

Xie W, Albertsen LC, Eis-Janzyk G et al. · Science translational medicine · (2026) · View on PubMed ↗

---

Kidney–Cardiovascular–Metabolic (CKM) Syndrome & CKD Prevention

Executive Summary of the ASN Kidney Health Guidance on the Cardiovascular‑Kidney‑Metabolic Syndrome.

This article studied and summarized the ASN Kidney Health Guidance on the cardiovascular–kidney–metabolic (CKM) syndrome, including an executive summary of recommended assessment and prevention strategies. It emphasizes routine CKM risk assessment, use of cardiovascular risk equations in chronic kidney disease to guide preventive therapies, and coordinated, comprehensive CKD-based treatment to reduce treatment gaps. The guidance is clinically significant because it provides a framework to integrate cardiovascular, metabolic, and kidney care to improve outcomes in high-risk CKD populations.

Navaneethan SD, Rifkin B, Mottl AK · Journal of the American Society of Nephrology : JASN · (2026) · View on PubMed ↗

ASN Kidney Health Guidance on the Cardiovascular-Kidney-Metabolic Syndrome.

This guidance document studied the implications of the cardiovascular–kidney–metabolic (CKM) syndrome framework for people with kidney disease. It highlights the need for cardiovascular screening approaches tailored to CKD risk and notes that multiple pharmacotherapies targeting CKM syndrome can improve both cardiovascular and kidney outcomes. The scientific/clinical significance is an integrated prevention-and-treatment strategy that addresses the interconnected drivers of atherosclerotic cardiovascular disease in CKD.

Bansal N, Bjornstad P, Bress AP et al. · Journal of the American Society of Nephrology : JASN · (2026) · View on PubMed ↗

---

Vaccines & Respiratory Virus Prevention (Influenza/RSV/COVID-19)

COVID-19 Vaccine Effectiveness and Safety for the 2026-2027 Respiratory Season.

This systematic review studied COVID-19 vaccine effectiveness and safety for the 2026–2027 respiratory season in the US by synthesizing newly published evidence. The authors searched major databases (Cochrane Central, PubMed/MEDLINE, Embase, Scopus) from August 1, 2025 to June 29, 2026 and summarized studies reporting vaccine effectiveness/efficacy and safety outcomes. The results are significant for informing public health and clinical decisions on ongoing vaccine recommendations and risk–benefit assessment during the upcoming respiratory season.

Lipson RA, Senerth E, Watson MA et al. · JAMA · (2026) · View on PubMed ↗

Influenza Vaccine Effectiveness and Safety for the 2026-2027 Respiratory Season.

This systematic review evaluated the effectiveness and safety of US-licensed seasonal influenza vaccines across multiple influenza seasons in the US, updating evidence through June 30, 2026. It found that seasonal influenza vaccination reduces influenza severity and lowers risks of hospitalization and death, particularly among high-risk groups. These updated findings support continued use of current influenza vaccines for reducing severe outcomes during the 2026–2027 respiratory season.

Senerth E, Sheikholeslamian SM, Sivakumaran K et al. · JAMA · (2026) · View on PubMed ↗

RSV Immunization Effectiveness and Safety for the 2026-2027 Respiratory Season.

This systematic review synthesized evidence on RSV vaccine and RSV monoclonal antibody effectiveness and safety, along with US RSV epidemiology, using randomized trials and observational studies published through June 29, 2026. It concluded that US-licensed RSV prevention products (vaccines and monoclonal antibodies) provide measurable protection against RSV disease while maintaining acceptable safety profiles. The review informs clinical and public health decision-making for RSV prevention in the 2026–2027 respiratory season.

Senerth E, Sheikholeslamian SM, Babatunde I et al. · JAMA · (2026) · View on PubMed ↗

---

---

Generated automatically on September 04, 2026 from PubMed’s trending articles. Summaries are AI-generated; always consult the original publication for clinical or research decisions.